Sonali Gattani

The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.

Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.

Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.

Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.

Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.

Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.

Stringent CR criteria may not predict clinical outcomes for patients with multiple myeloma.